Comparing a Survivin Inhibitor to Carboplatin for Treating Small Cell Lung Cancer in vitro

We find inhibition of survivin using YM155 to be more potent (lower-dose requirements) than the traditional, platinum-based chemo-therapy carboplatin with the same maximal efficacy (loss of cell-viability) when treating small cell lung cancer cells in vitro.

Posted by John Lee on Thursday, May 20th, 2021 in May 2021, chemotherapy, Small Cell Lung Cancer, Survivin, YM155

Read more